Faron Appoints Panmure Gordon as Joint Broker

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

Faron Appoints Panmure Gordon as Joint Broker

TURKU - FINLAND 22 April 2016 - Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), a drug discovery and development company, announces today the appointment of Panmure Gordon (UK) Limited ("Panmure Gordon") as Joint Broker to the Company with immediate effect. Whitman Howard will continue to act as Joint Broker to the Company.

- END -

For more information, please contact:

Faron Pharmaceuticals Oy

Katja Wallenlind

Phone: +358 (50) 577 4807

E-mail: katja.wallenlind@faronpharmaceuticals.com

Hume Brophy, PR

Mary Clark, Eva Haas, Hollie Vile

Phone: +44 207 862 6390

E-mail: faron@humebrophy.com

Cairn Financial Advisers LLP, Nominated Adviser

Emma Earl, Tony Rawlinson, Rebecca Anderson

Phone: +44 207 148 7900

Panmure Gordon (UK) Limited, Joint Broker

Freddy Crossley, Duncan Monteith (Corporate Finance)

Tom Salvesen (Corporate Broking)

Phone: +44 207 886 2500

Whitman Howard Limited, Joint Broker

Ranald McGregor-Smith, Francis North

Phone: +44 207 659 1234

About Faron Pharmaceuticals Ltd.

Faron is a drug discovery and development company focused on creating novel treatments for medical conditions with significant unmet needs. The Company is based in Turku, Finland. The Company currently has a pipeline of clinical stage products focusing on acute organ traumas, cancer immunotherapy and vascular damage. The Company's lead candidate Traumakine®, has been developed to treat acute respiratory distress syndrome ("ARDS"), a rare, severe, life threatening medical condition characterised by widespread inflammation in the lungs. Traumakine® is now in a pan-European pivotal Phase III study (INTEREST). Besides Traumakine®, Faron's pipeline consists of early stage assets including a pre-clinical anti-Clever-1 antibody named Clevegen. Clevegen is focused on converting the immune environment around a tumour from being immune suppressive to immune stimulating and represents a novel immuno-oncology approach. Faron Pharmaceuticals Oy is listed on AIM under the ticker 'FARN'. Further information is available at www.faronpharmaceuticals.com